Clinical Trial: 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional
Official Title: 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Brief Summary: Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET Scan is a novel scanning method that may have improved sensitivity and resolution specifically for neuroendocrine tumors. Patients with neuroendocrine tumors will be imaged with this agent and it will be compared to conventional imaging methods to determine the safety and efficacy of this radiopharmaceutical.
Detailed Summary:
Sponsor: Ochsner Health System
Current Primary Outcome: Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 5 years ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Number of lesions detected by 68Ga-DOTATATE compared to conventional imaging techniques [ Time Frame: 5 years ]
- We want to determine if the 68Ga-DOTATATE PET Scan changes care plans compared to conventional imaging/diagnostic techniques (Octreoscan, MRI, CT) [ Time Frame: 5 years ]
Original Secondary Outcome: Same as current
Information By: Ochsner Health System
Dates:
Date Received: January 14, 2014
Date Started: March 2014
Date Completion:
Last Updated: January 16, 2014
Last Verified: January 2014
